Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Chelsea Therapeutics International's CEO Discusses Q4 2011 Results - Earnings Call Transcript

Stock quotes in this article: CHTP 

Chelsea Therapeutics International, Ltd. (CHTP)

Q4 2011 Earnings Call

March 6, 2012 4:30 pm ET

Executives

Kate McNeil - Director, IR

Simon Pedder - President and CEO

Nick Riehle - CFO

Art Hewitt - CSO

Bill Schwieterman - CMO

Keith Schmidt - VP, Marketing and Sales

Analysts

Robyn Karnauskas - Deutsche Bank

Liana Moussatos - Wedbush Securities

Alan Carr - Needham & Company

Jonathan Eckard - Leerink Swann

Juan Sanchez - Ladenburg

Presentation

Operator

Good day, and welcome to the Chelsea Therapeutics International fourth quarter conference call. (Operator Instructions) I would now like to introduce the host for today's conference, Ms. Kate McNeil, Director of Investor Relations.

Kate McNeil

Good afternoon and welcome to Chelsea Therapeutics fourth quarter and full year 2011 conference call. We announced our fourth quarter full year 2011 results this afternoon after the close of the U.S. financial markets and our press release can be found on our website at www.chelseatherapeutics.com.

Joining me from Chelsea Therapeutics is Dr. Simon Pedder, President and Chief Executive Officer; Mr. Nick Riehle, Chief Financial Officer; Dr. Art Hewitt, Chief Scientific Officer; Dr. Bill Schwieterman, Chief Medical Officer; and Mr. Keith Schmidt, Vice President of Marketing and Sales.

Before I turn the meeting over to Dr. Pedder, let me note that some of the remarks you'll hear today may contain forward-looking statements about the company's performance. Actual future results might differ materially from those projected in these forward-looking statements.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%
US 10 Yr 1.949% +0.084

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs